Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2013 / Article
Special Issue

TCM Zheng Classification and Clinical Trials

View this Special Issue

Research Article | Open Access

Volume 2013 |Article ID 738245 | https://doi.org/10.1155/2013/738245

Shujun Sun, Jianye Dai, Junwei Fang, Xiaojun Gou, Huijuan Cao, Ningning Zheng, Yang Wang, Wei Zhang, Yongyu Zhang, Wei Jia, Yiyang Hu, "Differences of Excess and Deficiency Zheng in Patients with Chronic Hepatitis B by Urinary Metabonomics", Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 738245, 10 pages, 2013. https://doi.org/10.1155/2013/738245

Differences of Excess and Deficiency Zheng in Patients with Chronic Hepatitis B by Urinary Metabonomics

Academic Editor: William C. Cho
Received10 Jan 2013
Revised25 Mar 2013
Accepted25 Mar 2013
Published24 Apr 2013


Traditional Chinese medicine (TCM) physicians stratify patients with the same disease into different subtypes in order to guide the appropriate treatment, which is called Zheng (TCM syndrome) classification. Excess and deficiency ZHENG is a couple of basic ZHENGs of maladjusted body nature, reflecting the struggling state of human body and pathogenic factor and is important and prevalently exists in the ZHENG classification of many diseases. The present work using chronic hepatitis B (CHB) as an entry point explored the substance connotation of excess and deficiency ZHENG with the metabonomic technology based on gas chromatography-mass spectrometry (GC-MS). The different substantial basis of two ZHENGs suggested that CHB patients could be categorized into two groups with diverse pathogenesis. The differential metabolites and disturbed pathways compared to not-obvious ZHENG characters patients (without ZHENG group/WZ) were selected in both of the two ZHENGs. The ROC analysis demonstrated that five metabolites had a greater potential to be the clinic biomarkers of EZ or DZ. And excess ZHENG revealed a higher level of immune function than deficiency ZHENG. We are eager to transform the concept of traditional excess and deficiency ZHENGs to modern therapeutic approaches, with the prospect to help to promote personalized medicine.

1. Introduction

As an important part of complementary and alternative medicine [1], traditional Chinese medicine(TCM) plays an important role in people’s healthcare and is gaining in popularity [2] with its efficacy evidence increasing [3, 4]. It performs treatment based on ZHENG (translated as syndrome or pattern) Classification which is called “bian zheng lun zhi.” Owing to the manifestationin different syndromes, patients with the same disease would be treated differently by TCM practitioners [3], which is called “tong bing yi zhi” in Chinese. And one TCM therapy or formula should be specifically corresponded with a ZHENG, not a disease [5], and serious side effects could be caused by the abuse or misuse without any consideration of the ZHENG Classification [6, 7]. To demonstrate the importance of ZHENG classification, many studies have been conducted [8, 9]. For example, it was demonstrated in our previous experiment that if different ZHENGs of hepatitis-B-caused cirrhosis patients were treated by the same therapy, they would display various responses [10]. Furthermore, in a recent report, a biomedical therapy showed different effective rates for the rheumatoid arthritis patients with various TCM syndromes [11], which indicated that ZHENG was a subtype of the disease and would show some revelations for better individualized treatment in mainstream medicine.

ZHENG depicts a whole pathological state of a patient by the profiles of symptoms, pulse feelings, and tongue appearance [12]. However, scientists cannot explain it with the mainstream medicine terminology. The introduction of system biology including genomics, proteomics, and metabonomics, facilitates the translation of TCM concepts into mainstream medicine based on biochemical, pathway or regulatory processes [13]. Lu et al. have built up the molecular networks of TCM cold and hot ZHENG in rheumatoid arthritis (RA) by network analysis [14]. Li et al. found the potential biomarkers of “Kidney-Yang deficiency syndrome” and the related disturbed pathway with the method of urine metabonomics [15].

Chronic hepatitis B (CHB) infection continues to be a global health problem [16]. As reported by World Health Organization (WHO) at 2012, an estimated 350 million people have been affected with CHB worldwide. About 600 000 people died every year due to the consequences of hepatitis B (http://www.who.int/mediacentre/factsheets/fs204/en/index.html). And the cure of CHB is never an easy task and there still remains further progress. TCM treatment guided by “bian zheng lun zhi” or combination with Westerntreatment can get a higher effective response rate [17]. Excess ZHENG (EZ) and deficiency ZHENG (DZ) is a double of basic ZHENGs of maladjustment body nature, reflecting the struggling state of human body and pathogenic factor. But the substantial basis or connotation of EZ and DZ is still unknown. The present paper designed a urine metabonomic study based on GC-MS to classify EZ and DZ patients with CHB patients and to map the substantial connotation of the two TCM ZHENGs by comparing EZ/DZ groups with the without ZHENG group (WZ) which was made up of the not-obvious ZHENG characters CHB patients. To our knowledge, this study is the first report of the classification of EZ and DZ based on CHB with urinary Metabonomics.

2. Materials and Methods

2.1. Chemicals and Drugs

N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA + TMCS 99 : 1) and urease were purchased from Sigma Corporation of American. Methoxyamine hydrochloride, heptane, methanol, ethanol, acetonitrile, acetone, chloroform and pyridine were analytical grade from China National Pharmaceutical Group Corporation in Shanghai of China. L-2-Chlorophenylalanine and heptadecanoic acid (also provided by Sigma Corporation of America) were used as an internal quality standard. The ultrapure water was obtained from a Milli-Q system (Millipore, USA).

2.2. Subjects and Experiment Design

Three groups of CHB patients with EZ, DZ, and WZ and healthy volunteers group were enrolled in the study from Shuguang hospital of China. The numbers of cases were 30, 23, 30, and 20, respectively. All enrolled objects of the study were aged 18–65. The clinical study was approved by the local ethics committee and all of the recruited persons were given informed consent. And the study was performed in accordance with the principles contained in the Declaration of Helsinki. Diagnostic standard of HB patients was referred to “The guideline of prevention and treatment for chronic hepatitis B” [18]. TCM ZHENG classification was referred to as the viral hepatitis diagnostic standard described by the Internal Medicine Hepatopathy Committee of Chinese Traditional Medicine Association in December, 1991 [19]. All patients were diagnosed by junior Chinese medical physicians and then identified by three chief or deputy physicians; those who were consistently diagnosed as EZ or DZ by all of the physicians were enrolled in our study [20]. In addition, there is an exclusion criterion of CHB: (1) cases complicated with other hepatotropic virus hepatitis, (2) chronic severe hepatitis, (3) associated with serious primary disease of heart, kidney, lung, endocrine, blood, metabolic and gastrointestinal; or psychotic patients, (4) pregnant or lactating women.

2.3. Sample Collection and Preparation

A complete physical examination was given; the health condition was recorded on a scale including the information obtained through four traditional examination methods: looking, listening and smelling, asking, and touching at the patient’s entry into the study, and the urina sanguinis and vein blood were collected from all enrolled subjects. Urine and blood samples were stored at –80°C until GC-MS assay and the blood was utilized to detect the indicators of main medicine such as ALT and AST.

All these urine samples were thawed in ice water bath and vortex-mixed before analysis. Each 1 mL aliquot of standard mixture or urine sample was placed into a screw tube, 10 min centrifugation (12,000 rpm) was given, and aliquots of 150 μL supernatant were transferred into another screw tube. After adding 70 μL of urease (4 mg/mL) and vortex-mixing for 30 s, samples were conditioned at 37°C for 15 min to remove the urea. After the addition of 800 μL of methanol and 10 μL of myristic acid in methanol (1 mg/mL) and mixing for 1 min, the solution was centrifuged at 13,000 rpm for 10 min. Then a 200 μL aliquot of supernatant was transferred into a GC vial and evaporated to dryness under N2 at 30°C. 50 μL of methoxyamine in pyridine (15 mg/mL) was added to the GC vial, vortex-mixed for 1 min, and the methoximation reaction was carried out for 90 min rocking in a shaker at 30°C, then 50 μL of BSTFA plus 1% TMCS was added to the samples for trimethylsilylation for another 1 h at 70°C. At last, 30 μL of heptane containing external standard methyl myristate was added to the GC vial, and the solution was analyzed utilizing GC-MS after vortex for 30 s.

2.4. Data Acquisition

One hundred and fifteen items of TCM symptoms and 67 items of biochemistry indicators of all objects were collected and recorded in the scales well designed before. and the list of 115 items of TCM symptoms and 67 items of biochemistry indicators could be found in the attachment with Supplementary Material available online at http://dx.doi.org/10.1155/2013/738245.

All GC-MS analyses were performed by a mass spectrometer 5975B (Agilent technologies, USA) coupled to an Agilent 6890 (Agilent technologies, USA) gas chromatography instrument. In the gas chromatographic system, a capillary column (Agilent J&W DB-5ms Ultra Inert 30 m × 0.25 mm, film thickness 0.25 μm) was used. Helium carrier gas was used at a constant flow rate of 1.0 mL × min–1. One μL of derivatized samples was injected into the GC/MS instrument, and splitless injection mode was used. A programmed column temperature was optimized to acquire a well separation, which was demonstrated in Table 1. The temperatures of the injection port, the interface, and source temperature were set at 280°C, 260°C, and 230°C, respectively. The measurements were made with electron impact ionization (70 eV) in the full scan mode (m/z 30–550). The solvent post time was set to 5 min. The GC-MS operating condition was the same as the previous experiment [10] except the column temperature program.

Rate (°C/min)Temperature (°C)Hold time (min)


2.5. Data Analysis

Information of biochemical indicators and TCM symptoms was extracted from the scales and formed an excel matrix, then were analyzed in Smica-p11.5 Software (Umetrics, Umea, Sweden) for the analysis of principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), orthogonal projection to latent structures (OPLS) and spss 17.0 (SPSS, Chicago, IL, USA) for Mann-Whitney U test.

As to the profiles obtained from GC-MS, wispy shifts in retention time between fingerprints occur due to experimental variations and column aging. When the total ion current chromatograms (TICs) were obtained, peak-alignment or warping techniques are commonly applied to compensate for minor shifts in retention times. Thus, in the subsequently data processing, the same variable manifested synchronous information in every profile. So all the GC-MS raw files after being converted to CDF format via the software coming with Agilent MSD workstation, were subsequently processed by the XCMS toolbox (http://metlin.scripps.edu/download/) using XCMS’s default settings with the following exceptions: xcmsSet (full width at half maximum: fwhm = 5; S/N cutoff value: snthresh = 10, max = 15), group (bw = 5). The resulting table (CSV file) was exported into Microsoft Excel (Microsoft Inc., USA), where normalization was performed prior to multivariate analyses. The resulting three-dimensional matrix involving peak index (RT-m/z pair), sample names (observations), and normalized peak area percent was introduced into Simca-P 11.5 Software (Umetrics, Umea, Sweden) for the analysis of PCA, PLS-DA, and OPLS. Differential variables with VIP values [21] exceeding 1.5 between two different groups could be generated from loadings plot. Subsequently, those variables were further analyzed by Mann-Whitney U test to confirm the changed metabolites by SPSS 17.0 (SPSS, Chicago, IL, USA) with the threshold of P value set at 0.05. Those variables, then, were identified by searching in NIST 2005 database and verified by standards. Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.genome.ad.jp/kegg/) and Metabolites Biological Role (MBRole) (http://csbg.cnb.csic.es/mbrole) were based to select the related pathway. Many references were searched to give the biochemical interpretation of changed metabolites disturbed pathways of EZ and DZ in CHB.

3. Results

3.1. ZHENG Classification
3.1.1. ZHENG Classification by Biochemical Indicators

Sixty-seven indicators of two groups of patients were analyzed by PCA, PLS-DA, and OPLS analyses attending to differentiate objects of EZ and DZ. Automatic modeling parameters indicated the poor explanation and predication of the models as shown in Table 2, meaning that the two ZHENGs could not be distinguished by profiles of biochemical indicators.

ModelAmount of components


and represent the cumulative sum of squares (SS) of all the ’s and ’s explained by all extracted components.
is an estimate of how well the model predicts the ’s.

Table 3 showed us clinical information of two groups of CHB-affected patients based on western medical diagnostic approach. The commonly used indexes revealed no significant difference between the ZHENG groups by analysis of Mann-Whitney U test. It was illustrated that classification of EZ and DZ was irrelevant to these indexes.

IndexesExcess ( )Deficiency ( )

Systolic pressure (mmHg)114.90 ± 10.51113.88 ± 8.230.378
Diastolic pressure (mmHg)75.69 ± 7.8676.6 ± 5.870.112
Age (years)40.39 ± 14.5839.5 ± 11.80.809
Gender (M/F)31/725/90.277
ALT (IU/L)61.26 ± 47.4350.8 ± 55.40.378
AST (IU/L)43.84 ± 19.645.96 ± 40.520.112
HBsAb (IU/mL)2.20 ± 10.037.16 ± 28.960.107
TBIL (µmol/L)17.56 ± 7.5717.43 ± 6.030.245
DBIL (µmol/L)6.1 ± 4.174.82 ± 1.820.817
IDBIL (µmol/L)11.45 ± 4.0212.62 ± 4.920.062
GGT (IU/L)49.55 ± 64.3929.52 ± 14.680.811
ALP (IU/L)94.71 ± 36.0679.84 ± 20.810.489
TP (g/mL)76.77 ± 7.9979.34 ± 5.520.921
ALB (g/mL)44.59 ± 4.445.99 ± 2.290.373

3.1.2. ZHENG Classification by Symptoms

One hundred and fifteen TCM symptoms were analyzed by OPLS which could effectively extract variables responsible for the separation by removing variables unrelated to pathological status. Two groups could be absolutely separated as shown in the score plot (Figure 1(a)) with modeling (Model 1) information listed in Table 4.


Model 11P + 1O0.1050.8870.582
Model 21P + 3O0.5010.8150.215
Model 31P + 2O0.420.5680.216
Model 41P + 4O0.5520.8040.258
Model 51P + 2O0.2930.7310.351
Model 61P + 2O0.4710.6210.361

Model 1 was generated by EZ group compared with DZ group with TCM symptoms; Models 2–6 were generated by urine metabonomic data (Model 2: EZ group compared with DZ group; Model 3: CHB group compared with normal control; Model 4: comparison of EZ, DZ, and WZ; Model 5: EZ compared with WZ; Model 6: DZ compared with WZ.)
No represents the sum number of components. For instance, “1P + 1O” means one predictive component and two orthogonal components for establishing the OPLS model.
and represent the cumulative sum of squares (SS) of all the ’s and ’s explained by all extracted components.
is an estimate of how well the model predicts the ’s.
3.1.3. ZHENG Classification by Metabonomics

The matrix obtained by GC-MS based metabonomics could also classify the two ZHENG types in an OPLS score plot (Figure 1(b)). The model parameters are shown as Model 2 in Table 4. The plot showed that the two TCM types could not only be distinguished by TCM symptoms but also be classified by urine metabolic profiles, which was one of the evidences of material foundation of ZHENG. Subsequent analysis of differential metabolites and related pathways might explain the substance connotation of classification for these two ZHENGs.

3.2. The Substance Connotation of DZ and EZ
3.2.1. Metabolic Profiles of Chronic Hepatitis B Patients and Healthy Control

The urine profiles of all the CHB patients and healthy volunteers (normal group) were analyzed by OPLS analysis. And Model 3 was calculated between CHB and normal group. The score plots were shown in Figure 2(a) and the modeling parameters were listed in Table 4.

The three groups of CHB patients including EZ, DZ and WZ groups were also separated by OPLS analysis, which was depicted by the score plot (Figure 2(b)) and the modeling parameters were listed in Table 4 (Model 4). The results illustrated that different ZHENGs in CHB patients had their own substance basis or connotation.

3.2.2. Changed Metabolites Compared to WZ

The profiles from EZ (or DZ) CHB patients not only contained the information of different ZHENGs but were also involved in CHB disease. In order to explore the connotation of EZ and DZ, the disease factors should be eliminated. Therefore, data of EZ (or DZ) group was compared with data of WZ group which was made up of not-obvious ZHENG characters patients. The OPLS score plots were shown by Figure 3 and modeling parameters were listed in Table 4 (Model 5 and Model 6). The OPLS loading plots were made to screen out the specific variables contributing to the distinction between each ZHENG and WZ group. And the identified differential compounds and corresponding VIP values were listed in Table 5. All the differential compounds in the two ZHENGs were subsequently analyzed by Mann-Whitney U test compared to WZ group, respectively (P values were listed in Table 5) subsequently. The changing trend of differential metabolites was depicted by Figure 4.

GroupChanged metabolitesVIP FNDZ/WZFNEZ/WZAUCROC

EZGlycine2.100.0250.56 0.72 0.632
EZPropanoic acid1.740.0430.75 1.35 0.678
EZEthanimidic acid1.880.0390.74 1.36 0.671
EZThiomorpholine2.080.0210.50 0.71 0.588
EZButanedioic acid2.240.0070.47 0.67 0.601
EZL-Threonine1.640.0490.97 1.34 0.618
EZ2-Propenamide1.660.030.66 0.72 0.672
EZL-Phenylalanine2.110.0190.85 1.42 0.655
EZD-Ribose1.860.0050.74 1.52 0.732
EZRibonic acid1.700.010.71 1.47 0.711
EZCyclohexanone2.030.0030.66 1.55 0.744
EZInositol1.710.0140.92 1.45 0.649
EZButanedioic acid1.710.0110.92 1.47 0.65
EZD-Gluconic acid1.930.0120.81 1.41 0.661
EZUric acid2.450.0001.26 1.90 0.726
EZ3-(3,4-Dihydroxyphenyl)lactic acid2.030.0160.80 1.43 0.66
EZ1H-Indole-3-acetic acid1.960.0070.70 1.50 0.695
EZGulonic acid1.620.0420.96 1.35 0.619
EZXylonic acid2.030.010.80 1.47 0.697
EZMaltose2.080.010.47 0.68 0.577
EZGalactopyranoside2.070.0110.49 0.68 0.584
EZD-Glucose2.50.0010.46 0.61 0.617
DZButanoic acid1.550.020.52 0.84 0.655
DZGlycine1.530.0340.54 0.80 0.604
DZL-Alanine1.910.010.50 0.73 0.639
DZThiomorpholine2.040.0090.50 0.71 0.632
DZButanedioic acid1.920.0030.47 0.67 0.641
DZPropanedioic acid1.220.0161.12 1.57 0.589
DZCyclohexanecarboxylic acid1.620.0070.49 0.93 0.695
DZD-Ribose1.510.0061.18 1.22 0.675
DZRibitol1.420.0061.18 1.22 0.675
DZXylopyranoside1.230.0290.54 1.15 0.705
DZUric acid2.390.0011.26 1.90 0.591
DZMaltose1.410.0340.54 0.89 0.646
DZD-Xylose1.760.0090.50 0.88 0.678
DZGalactopyranose1.780.0090.50 0.88 0.678
DZMaltose,621.710.0110.50 0.82 0.654
DZGalactopyranoside1.690.0130.51 0.88 0.665
DZD-Glucose2.040.0030.46 0.61 0.658

EZ represents excess ZHENG patients group, DZ represents deficiency ZHENG patients group.
VIP means the variable importance in the project.
value was obtained from Mann-Whitney test (ZHENGs compared to WZ group).
FNDZ/WZ or FNDZ/WZ is fold change of mean ranks calculated by the differential metabolites of CHB with excess or deficiency ZHENG/the differential metabolites of CHB without ZHENG.
AUCROC means the area under the ROC curve.
3.2.3. Sensitivity and Specificity of Potential Markers for TCM Syndrome Classification

To determine the sensitivity and specificity of potential urine metabolic biomarkers of different TCM ZHENGs, ROC analysis was conducted. WZ group and DZ (/EZ) group were put together and defined as the non-EZ (/DZ) group, and so ROC analysis was carried out for discriminating EZ/DZ group with non-EZ/DZ group. The area under the ROC curves (AUC) for the differential metabolites was listed in Table 5. Among all the metabolites, the AUC values of xylopyranoside, ribonic acid, uric acid, d-ribose, and cyclohexanone fell into the range of 0.7–0.9. The ROC curves for classification of EZ/DZ group and non-EZ/DZ group were shown in Figure 5. It was suggested that the quantification of these five metabolites was more useful to classify excess and deficiency ZHENGs.

4. Discussion

In present work, it was the first time to stratify the EZ and DZ in CHB patients with the metabonomic technology. The results illustrate that the clinical biochemical indicators could not represent the characteristics of ZHENG. The clear separation between two groups by TCM symptoms and metabolic profiles illustrated that EZ and DZ had their substance fundaments. In order to eliminate the disease factors and explore the connotation of ZHENG, EZ (or DZ) group was compared with WZ group. Consequently, 22 and 17 differential metabolites from EZ and DZ were selected, respectively. The ROC curves of all the metabolites were conducted and five of them showed a higher sensitivity and specificity for the diagnosis of EZ or DZ (xylopyranoside for the diagnosis of DZ and ribonic acid, uric acid, d-Ribose and cyclohexanone for the diagnosis of EZ). It was suggested that these five metabolites were more potential to become the clinic biomarker of EZ or DZ.

By searching in KEGG database and website of MBRole, the disturbed pathways in patients with either EZ or DZ were extracted based on the differential metabolites and were listed in Table 6. From the result, we could know that 6 pathways turned up imbalanced in both EZ, and DZ, 2 pathways were disturbed in EZ and 3 were disturbed in DZ with the same disease background. While the 6 common disturbed pathways revealed difference between EZ and DZ, either. For instance, glycine, d-ribose, maltose, galactopyranoside, and d-glucose are four related differential metabolites of ABC transporters, and they are all differential for EZ and DZ compared with WZ group. Functions of ABC transporters include the transport of toxic compounds [22]. while from bar diagram of Figure 4, we could get that the content of them was higher in EZ than in DZ which might be one of the manifestations of vital Qi deficiency in patients with DZ. EZ patients had a higher detoxified ability than DZ, which might correspond with the idea of “the vital Qi of EZ patient has not been deficient yet” in TCM theory.

Pathway -val
EZ versus WZ
DZ versus WZ

ABC transporters<0.0001<0.0001Environmental information processingTwo ZHENGs in common
Pentose phosphate pathway<0.0001<0.0001Carbohydrate metabolismTwo ZHENGs in common
Aminoacyl-tRNA biosynthesis0.0030.006Carbohydrate metabolismTwo ZHENGs in common
Galactose metabolism0.0120.009Carbohydrate metabolismTwo ZHENGs in common
Starch and sucrose metabolism0.0180.015Carbohydrate metabolismTwo ZHENGs in common
Pentose and glucuronate interconversions0.0200.029Genetic information processingTwo ZHENGs in common
Ascorbate and aldarate metabolism<0.0001>0.05Carbohydrate metabolismSpecific for EZ
Glycine, serine, and threonine metabolism0.017>0.05Amino acid metabolismSpecific for EZ
Alanine, aspartate, and glutamate metabolism>0.050.003Amino acid metabolismSpecific for DZ
Amino sugar and nucleotide sugar metabolism>0.050.003Carbohydrate metabolismSpecific for DZ
Glycolysis/gluconeogenesis>0.050.005Carbohydrate metabolismSpecific for DZ
Purine metabolism>0.050.042Nucleotide metabolismSpecific for DZ

-val: the statistical significance of each pathway obtained from analysis of MBRole.
Class: categorization of each pathway obtained from KEGG.

In addition, successful clearance of the virus as well as the formation of liver diseases was largely driven by a complex interaction between the virus and the host immune response in CHB patients [23], while the lower immune function in DZ than in EZ was reported in more than one research [2426].

All above results suggest the ZHENG classification by symptoms profile has its fundaments. In other words, the pathomechanism and body state underlying different ZHENGs are discrepant, and the therapy and dosages should be tailored to each patient. The difference of immune function between EZ and DZ could interpret the TCM theory “treat excess by purgation and treat deficiency by tonification” to some extent. The present approach is transforming concepts of EZ and DZ to modern therapeutic approaches and will help to promote personalized therapy.

Other limitations in this report are as follows. (1) The study was under a small sample size, and the lager population study should be further researched. (2) Because the first step is to differentiate excess and deficiency during the ZHENG diagnosis of CHB, only those two ZHENGs in CHB were discussed in this study. As two basic ZHENGs, however, either of them can be subdivided. For instance, liver-gallbladder dampness-heat ZHENG (one of EZ) has a high incidence rate of 12.1% [27] in CHB patients and its connotation awaits understanding.

5. Conclusion

The present paper firstly explored the classification and substance connotation of excess and deficiency ZHENG in CHB patients with metabonomic technology. We find that clinical biochemical indicators cannot represent the characteristics of the two ZHENGs because of poor classification. The TCM symptoms and urinary metabolic profiles can successfully distinguish the two ZHENGs. Twenty-two and seventeen differential metabolites were extracted from EZ and DZ, respectively, compared with WZ group. From the result of ROC curves, it was revealed that five differential metabolites had a greater potential to be the clinic biomarkers of EZ or DZ (xylopyranoside for the diagnosis of DZ and ribonic acid, uric acid, d-Ribose, and cyclohexanone for the diagnosis of EZ). And their related pathways were found, which showed the difference and intersection of their connotation. After further analysis, the immune function of EZ was demonstrated higher than that of DZ. The difference suggested that CHB patients could be categorized into two groups with diverse pathogenesis, which helps us transform the concept of traditional excess and deficiency ZHENGs to modern therapeutic approaches and prompts us to further individualized medicine.

Conflict of Interests

It is revealed that all the authors do not have a direct financial relation with the commercial identities mentioned in their paper that might lead to a conflict of interests for any of the authors.

Authors' Contribution

Shujun Sun, Jianye Dai, Junwei Fang, and Xiaojun Gou contributed equally to this work and should be considered cofirst authors.


This work is financially supported by Technology Innovation Supporting Project for Top-Grade Discipline Construction, National Science and Technology Major Project (2009ZX10004-601, 2012ZX10005001-004, and 2012ZX10005001-008), and Shanghai “085” Science and Technology Innovation Supporting Project for Top-Grade Discipline Construction.

Supplementary Materials

The names of 115 items of TCM symptoms and 67 items of biochemistry indicators, which were collected from all the patients and volunteers recruited in this study

  1. Supplementary Material


  1. S. Kumar Pal, “Complementary and alternative medicine: an overview,” Current Science, vol. 82, no. 5, pp. 518–524, 2002. View at: Google Scholar
  2. F. Cheung, “Made in china,” Nature, vol. 480, pp. 82–83, 2011. View at: Google Scholar
  3. J. L. Tang, B. Y. Liu, and K. W. Ma, “Traditional Chinese medicine,” The Lancet, vol. 372, no. 9654, pp. 1938–1940, 2008. View at: Google Scholar
  4. F. Cheung, “Enter the clinic,” Nature, vol. 480, pp. 94–95, 2011. View at: Google Scholar
  5. W. Y. Jiang, “Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science,” Trends in Pharmacological Sciences, vol. 26, no. 11, pp. 558–563, 2005. View at: Publisher Site | Google Scholar
  6. D. H. Zhou, “The research on modernization of Chinese herbal forms its side effect,” Research of Traditional Chinese Medicine, vol. 7, no. 1, pp. 47–48, 2001. View at: Google Scholar
  7. A. Yukiharu, “The truth of the accident-some patients died from side effects of Xiao Chai Hu Tang,” Journal of Tianjin University of Traditional Chinese Medicine, vol. 21, no. 1, pp. 47–48, 2002 (Chinese). View at: Google Scholar
  8. H. Wei, W. Pasman, C. Rubingh, S. Wopereis, and M. Tienstra, “Urine metabolomics combined with the personalized diagnosis guided by Chinese medicine reveals subtypes of pre-diabetes,” Molecular BioSystems, vol. 8, no. 5, pp. 1482–1491, 2012. View at: Google Scholar
  9. H. Van Wietmarschen, K. Yuan, C. Lu et al., “Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients,” Journal of Clinical Rheumatology, vol. 15, no. 7, pp. 330–337, 2009. View at: Publisher Site | Google Scholar
  10. S. Sun, J. Dai, W. Wang, H. J. Cao, and J. W. Fang, “Metabonomic evaluation of ZHENG differentiation and treatment by Fuzhenghuayu tablet in Hepatitis-B-caused Cirrhosis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 453503, 8 pages, 2012. View at: Publisher Site | Google Scholar
  11. Y. He, A. Lu, Y. Zha, and I. Tsang, “Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients,” Complementary Therapies in Medicine, vol. 16, no. 4, pp. 206–211, 2008. View at: Publisher Site | Google Scholar
  12. M. Jiang, C. Lu, C. Zhang, J. Yang, and A. Lu, “Syndrome differentiation in modern research of traditional Chinese medicine,” Journal of Ethnopharmacology, vol. 140, no. 3, pp. 634–642, 2012. View at: Google Scholar
  13. J. van der Greef, “All systems go,” Nature, vol. 480, p. 87, 2011. View at: Google Scholar
  14. C. Lu, X. Y. Niu, C. H. Xiao, G. Chen, and Q. L. Zha, “Network-based gene expression biomarkers for cold and heat patterns of rheumatoid arthritis in traditional chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 203043, 17 pages, 2012. View at: Publisher Site | Google Scholar
  15. X. Lu, Z. Xiong, J. Li, S. Zheng, T. Huo, and F. Li, “Metabonomic study on “Kidney-Yang Deficiency syndrome” and intervention effects of Rhizoma Drynariae extracts in rats using ultra performance liquid chromatography coupled with mass spectrometry,” Talanta, vol. 83, no. 3, pp. 700–708, 2011. View at: Publisher Site | Google Scholar
  16. Y. F. Liaw, N. Leung, J. H. Kao, T. Piratvisuth, and E. Ganeet, “Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update,” HepatolInt, vol. 2, pp. 263–283, 2008. View at: Google Scholar
  17. J. Guo, X. Fang, and C. Li, “Clinical analysis of TCM differential treatment on severe chronic hepatitis B,” Chinese Archives of Traditional Chinese Medicine, vol. 30, no. 10, pp. 2177–2179, 2012. View at: Google Scholar
  18. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Guide To Prevention and Treatment of Chronic Hepatitis B, 2005.
  19. “The standards of TCM differential syndromes of viral hepatitis,” Defined in December 1991 by Internal Medicine Hepatopathy Committee of Chinese Traditional Medicine Association. View at: Google Scholar
  20. T. Wu, M. Yang, H. F. Wei, S. H. He, and S. C. Wang, “Application of metabolomics in traditional chinese medicine differentiation of deficiency and excess syndromes in patients with diabetes mellitus,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 968083, 11 pages, 2012. View at: Publisher Site | Google Scholar
  21. L. Eriksson, E. Johansson, and N. Kettaneh-Wold, Multi and Megavariate Data Analysis—Part. 1: Basic Principles and Applications, Umetrics AB, Umeå, Sweden, 2nd edition, 2001.
  22. P. Borst and R. Oude Elferink, “Mammalian ABC transporters in health and desease,” Biochemistry, vol. 71, pp. 537–592, 2002. View at: Google Scholar
  23. J. Chang and S. R. Lewin, “Immunopathogenesis of hepatitis B virus infection,” Immunology and Cell Biology, vol. 85, pp. 16–23, 2007. View at: Google Scholar
  24. Q. Li, Z. Guo, J. Liang, W. Zhang, and L. M. Xu, “Interleukin-10 genotype correlated to deficiency syndrome in hepatitis B cirrhosis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 298925, 6 pages, 2012. View at: Publisher Site | Google Scholar
  25. P. Li, Q. Chen, and L. Xiao, “The correlation between RBC immune function and deficiency and excess syndromes in chronic hepatitis B,” Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, vol. 2, no. 3, pp. 28–29, 1992 (Chinese). View at: Google Scholar
  26. L. Zhou, J. Wei, Y. Liu, A. Cao, and X. Wang, “Studying the different waist of 874 cases of the obese patients “xushi” syndrome characteristics,” Liaoning Journal of Traditional Chinese Medicine, vol. 35, no. 11, pp. 1648–1649, 2008. View at: Google Scholar
  27. H. Y. Wang, H. M. Li, B. Yang, and J. J. Xu, “The relationship between distribution characteristics of TCM constitution and Syndromes in 141 patients with Fatty Liver,” Journal of Beijing University of TCM, vol. 33, no. 7, pp. 500–502, 2010 (Chinese). View at: Google Scholar

Copyright © 2013 Shujun Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles